NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02030561

Recruitment Status : Unknown

Verified June 2016 by National University Hospital, Singapore.
Recruitment status was: Recruiting

First Posted : January 8, 2014

Last Update Posted : June 22, 2016

Sponsor:

Collaborator:

National University, Singapore

Information provided by (Responsible Party):

National University Hospital, Singapore

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	August 2017
Estimated Study Completion Date :	August 2018

Publications:

Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni MA, Spadi R, Donadio M, Ciuffreda L, Matera L. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med. 2008 May 16;6:25. doi: 10.1186/1479-5876-6-25.

Voskens CJ, Watanabe R, Rollins S, Campana D, Hasumi K, Mann DL. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J Exp Clin Cancer Res. 2010 Oct 11;29:134. doi: 10.1186/1756-9966-29-134.

To Top